ACP
IRWD icon

Acuta Capital Partners’s Ironwood Pharmaceuticals IRWD Stock Holding History

Acuta Capital Partners’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-59,700
Closed -$654K – 72
2016
Q2 		$654K Buy
+59,700
New +$583K 0.31% 50

Other funds holding IRWD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acuta Capital Partners's IRWD Position: Q3 2016 in Review

Acuta Capital Partners sold out of Ironwood Pharmaceuticals (IRWD) in Q3 2016, closing a stake of 59,700 shares — an estimated $654K sold.

Acuta Capital Partners first reported a position in IRWD in Q2 2016 and held it in 1 quarter. The position peaked at $654K in Q2 2016. 155 funds tracked by Wall St. Rank hold IRWD as of Q3 2016.

  • Acuta Capital Partners reported no remaining Ironwood Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Acuta Capital Partners sold 59,700 Ironwood Pharmaceuticals shares in Q3 2016, an estimated $654K.
  • Acuta Capital Partners first reported a position in Ironwood Pharmaceuticals in Q2 2016 and held it in 1 quarter.
  • Acuta Capital Partners's Ironwood Pharmaceuticals position peaked at $654K in Q2 2016.
  • 155 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2016.

Based on Acuta Capital Partners's 13F filing for Q3 2016, filed 14 Nov 2016.